Key result
Immune checkpoint inhibitors can induce rare but potentially fatal cardiac adverse events, such as myocarditis, necessitating early detection and prompt initiation of high-dose corticosteroids.
Why the study?
Immune checkpoint inhibitors can cause rare but life-threatening and potentially fatal cardiac adverse events, making the elucidation of pathophysiology and establishment of management measures an urgent challenge in onco-cardiology.
This review outlines the pathophysiology, clinical presentation, and management of immune checkpoint inhibitor-related cardiac adverse events, emphasizing early detection and high-dose corticosteroids for myocarditis.
Alerts clinicians to monitor for rare but lethal ICI cardiotoxicity; leaves open optimal prevention and management strategies.
Onco-cardiology recently emerged as a novel discipline to provide effective cardioprotective care against cancer therapeutics-related cardiac adverse events (CAEs) and support the continuity of optimal cancer treatment. Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and dramatically improved outcomes in patients with advanced or refractory cancers. However, ICIs intrinsically stimulate systemic immune responses and can potentially induce a spectrum of immune-related adverse events (irAEs), which can affect any organs of the body. The manifestation of cardiac irAEs includes myocarditis, arrhythmias and conduction abnormalities, and pericardial diseases. Takotsubo-like cardiomyopathy is also included as a manifestation of ICI-related CAEs, but the pathophysiological relevance is unclear. Although the incidence is rare, ICI-related CAEs are life-threatening and potentially fatal. Elucidating pathophysiology and establishing management measures of ICI-related CAEs are one of the most urgent challenges in the field of onco-cardiology.
No takes yet. Share an insight, caveat, or question.
Kadowaki et al. (2021) conducted a review in Immune checkpoint inhibitor-related cardiac adverse events. Immune checkpoint inhibitors was evaluated. Immune checkpoint inhibitors can induce rare but potentially fatal cardiac adverse events, such as myocarditis, necessitating early detection and prompt initiation of high-dose corticosteroids.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: